Rose Bengal disodium

June 26, 2025 -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced the publication of preclinical research by Christine Chung, MD and her team (the “Chung Lab”) at Moffitt Cancer Center in Tampa, Florida (“Moffitt”), evaluating intratumoral PV-10 in models of head and neck squamous cell carcinoma (“HNSCC”). The study, published in Molecular Cancer Therapeutics, highlights novel mechanistic findings that could support future clinical development of PV-10 in locally recurrent HNSCC. The article, titled “PV-10 triggers immunogenic cell death in head and neck squamous cell carcinoma via endoplasmic reticulum stress and apoptosis,” is available here. PV-10, Provectus’s investigational cancer immunotherapy, is formulated from the Company’s pharmaceutical-grade rose bengal sodium (“RBS”) active pharmaceutical ingredient (“API”). Dominic Rodrigues, President and Vice Chair of the Board of Directors of Provectus, commented, “This important, multi-year research effort funded by the Chung Lab at Moffitt adds to our understanding of PV-10’s mechanistic effects—specifically its ability to induce immunogenic cell death in HNSCC. These results align with our broad immunotherapy platform, including a planned Phase 1 trial potentially later this year of intratumoral PV-10 in pre-operative penile squamous cell carcinoma at Moffitt.” Mr. Rodrigues added, “We’re deeply grateful to Dr. Chung and her Moffitt colleagues for their scientific rigor and dedication. Their work reflects the broader momentum building around our pharmaceutical-grade RBS platform.” Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases that are based on a class of synthetic small molecules called halogenated xanthenes. Provectus’s lead molecule is named Rose Bengal Sodium. Provectus’s medical science platform includes clinical development programs in oncology, dermatology, and ophthalmology; proof-of-concept in vivo programs in oncology, hematology, full-thickness cutaneous wound healing, and canine cancers; and in vitro discovery programs in infectious diseases, tissue regeneration and repair, and proprietary targets. The content above comes from the network. if any infringement, please contact us to modify.

KNOXVILLE, TN / ACCESSWIRE / January 14, 2025 / VisiRose Inc. (\"VisiRose\" or the \"Company\"), a privately-held, clinical-stage biotechnology company developing novel ocular therapeutics, today announced a $3 million seed financing round for VisiRose. The funds from this round will be directed toward advancing the Company\'s lead investigational program, particularly facilitating critical regulatory milestones of the clinical development of its therapies for corneal diseases and other severe ocular conditions.The proceeds from this financing round will support several key initiatives, including:Completing a pre-investigational new drug (IND) submission meeting with the U.S. Food and Drug Administration (FDA) for VisiRose\'s Rose Bengal Photodynamic Antimicrobial Therapy (RB PDAT), a groundbreaking, non-invasive, investigational treatment for infectious keratitis and other serious eye infections.Submitting an IND application for investigational drug PV-305, targeting corneal blindness (RB) through photodynamic therapy (PDAT), and working toward its acceptance by the FDA.Manufacturing an initial clinical supply of PV-305, enabling the Company to initiate clinical trials, undertake expanded access, and move closer to regulatory approval.VisiRose is leveraging the novel ocular RB PDAT research from the University of Miami\'s Bascom Palmer Eye Institute and Ophthalmic Biophysics Center, in collaboration with Provectus Biopharmaceuticals (OTCQB: PVCT). At the heart of the Company\'s therapeutic platform is Provectus\'s bioactive synthetic small molecule, Rose Bengal Sodium (RBS), to treat a range of sight-threatening ocular conditions with high unmet medical needs.\"We are pleased to complete this financing round to support the continued progress of our ophthalmology drug pipeline,\" said Dominic Rodrigues, Acting Chief Executive Officer of VisiRose. \"The funding will enable us to advance our lead drug product candidate PV-305 through critical regulatory steps, ultimately moving us closer to providing patients with innovative therapies for corneal diseases and other serious ocular conditions.\"Juan Carlos Navia, M.D. at Bascom Palmer Eye Institute at the University of Miami Miller School of Medicine, delivering the VisiRose RB PDAT treatment. Courtesy of Bascom Palmer Eye Institute About VisiRoseVisiRose is a newly launched, clinical-stage biotechnology company of the University of Miami and Provectus Biopharmaceuticals, focused on commercializing the Miller School of Medicine\'s Bascom Palmer Eye Institute and its Ophthalmic Biophysics Center\'s innovative ocular research using Provectus\'s bioactive synthetic small molecule Rose Bengal Sodium (RBS). For more information, please visit: https://visirose.com.Contact:VisiRose, Inc.Dominic RodriguesActing Chief Executive Officer[email protected]For Media Inquiries:Ira M. Gostin[email protected]775-391-0213SOURCE: VisiRose, Inc.Related Documents: